Honeywell International (NYSE: HON) is often overlooked as a pure-play quantum computing stock, but its Quantinuum subsidiary is one of the most advanced quantum computing platforms globally. Quantinuum’s trapped-ion technology has demonstrated industry-leading quantum volume and error correction, and the company has secured significant government and commercial contracts. With Honeywell’s strong balance sheet and diversified industrial base, HON offers a lower-risk way to gain exposure to quantum computing while benefiting from Honeywell’s core aerospace and automation businesses.
Investment Thesis
Quantinuum is positioned to capitalize on the growing demand for quantum computing in drug discovery, materials science, and cryptography. The company’s recent partnership with Microsoft and its involvement in the UK’s National Quantum Computing Centre provide near-term revenue visibility. Honeywell’s financial strength ensures Quantinuum has the resources to scale without dilutive equity raises, a key advantage over pure-play quantum startups.
12-Month Catalysts
- Launch of Quantinuum’s next-generation quantum processor with >100 logical qubits, expected in H2 2026.
- Expansion of commercial contracts with pharmaceutical and defense customers, potentially doubling Quantinuum’s revenue run rate.
- Potential spin-off or IPO of Quantinuum, unlocking shareholder value.
Key Risks
- Quantum computing remains an emerging technology; commercial adoption may be slower than expected.
- Honeywell’s core industrial businesses face cyclical headwinds, which could overshadow quantum progress.
Disclaimer: This is not financial advice. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Please consult a financial advisor before making investment decisions.